Why Is BHVN Stock Falling Premarket?

BofA downgraded Biohaven Pharmaceutical to ‘Underperform’ from ‘Neutral’ and cut the price target to $11, indicating a downside potential of about 26% from the stock’s previous close.

• The bank said the downgrade and the target cut reflect a "bearish view" on the risk-reward into the company’s Phase 3 data expected for its kv7 drug candidate in epilepsy in the second half of 2026. 
• Following the BofA downgrade, short interest in the company rose to a record high. 
• Earlier on Monday, Biohaven said the first patient in a Phase 3 trial evaluating BHV-1300 for Graves' disease had been enrolled.

Shares of Biohaven Pharmaceutical Holding Co. (BHVN) fell nearly 1.5% in the premarket session on Tuesday after a downgrade from Bank of America Corp. (BAC) triggered a selloff in the company’s shares.

According to TheFly, BofA downgraded the company to ‘Underperform’ from ‘Neutral’ and cut the price target to $11 from $12, indicating a downside potential of about 26% from the stock’s previous close.

BofA Rationale On BHVN Stock

The bank said the downgrade and the target cut reflect a "bearish view" on the risk-reward into the company’s next major near-term catalyst – the Phase 3 data expected for its kv7 drug candidate in epilepsy in the second half of 2026.

BofA said Biohaven trails Xenon's azetukalnar for epilepsy by at least two years, adding that it believes consensus expectations for $1 billion in peak sales could be at risk of downside without clear clinical differentiation.

BHVN Short Interest Climbs To Record High

Following the BofA downgrade, short interest in the company has risen. As per Koyfin data, short interest in the stock is at a record high, now at 16.70% compared to its lowest level of 3.50% in December 2022.

Phase 3 Trial For Graves' Disease Candidate

Earlier on Monday, Biohaven said that the first patient in a Phase 3 trial evaluating BHV-1300 for Graves' disease has been enrolled. The candidate is the first MoDE extracellular protein degrader designed to eliminate the disease-causing autoantibodies that drive Graves' disease, a condition that has not seen a new approved therapy in more than 70 years, the company said.

Across Phase 1 studies, the drug administered to nearly 200 patients demonstrated favorable tolerability, showing rapid reductions in disease-causing antibodies and normalization of thyroid hormone levels, the company said.

BHVN Stock: Retail Stance

Retail interest in the company shot up in the last 24 hours, with message volumes up 475% even as the sentiment remained in the “bullish” territory.

One user said, “Market sentiment for $BHVN is currently polarized. Clinical progress with the Phase 3 Graves' disease trial is being overshadowed by a BofA downgrade to "Underperform" and concerns over high cash burn.”

View this Stocktwits post

Another user commented, “Shorts coming out big time out of no where today on the forum, using the BofA news to scare as they are far underwater from shorting at 10 or 11.”

View this Stocktwits post

BHVN shares have gained nearly 38% so far in 2026.

For updates and corrections, email newsroom[at]stocktwits[dot]com.<